ALKSAlkermes plc
$40.63+46% 1Y
$40.63
$27.1352 weeks$52.99
The financials
Alkermes plc by the numbers
Alkermes plc (ALKS) reported revenue of $496M in Q2 2026 (quarter ended Jun 30, 2026), up 27% from the same quarter a year earlier. That came with a gross margin of 80% and net income of $501K (0.1% of revenue). For the full year FY2025, revenue was $1.48B (−5.2% year on year) and net income $242M. Its largest product in Q2 2026 was Vivitrol at $124M, 23% of the disclosed total, just ahead of Aristada And Aristada Initio at 18%. The next results filing is expected around Oct 27, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $496M | $391M | +27% |
| Gross profit | $398M | $341M | +17% |
| Operating income | $18M | $93M | −80% |
| Net income | $501K | $87M | −99% |
| Diluted EPS | $0.00 | $0.52 | to a loss |
| Product | Revenue | Share |
|---|---|---|
| Vivitrol | $124M | 23% |
| Aristada And Aristada Initio | $97M | 18% |
| LUMRYZ | $97M | 18% |
| LYBALVI | $94M | 17% |
| Manufactured Product And Royalty | $84M | 15% |
| Royalty | $27M | 5.0% |
| Manufacturing | $21M | 3.8% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $544.4M (+31%)
Manufacturing grew +183% year on yearRoyalty -9.4% year on year
Segment Latestquarter on quarteryear on year
- Vivitrol$124.5M$124.5Mquarter on quarter +11%year on year +2.3%+11%+2.3%
- Aristada And Aristada Initio$96.7M$96.7Mquarter on quarter +3.1%year on year -4.5%+3.1%-4.5%
- LUMRYZ$96.6M$96.6Mquarter on quarter +145%year on year n/a+145%n/a
- LYBALVI$94.0M$94.0Mquarter on quarter +1.7%year on year +12%+1.7%+12%
- Manufactured Product And Royalty$84.3M$84.3Mquarter on quarter +54%year on year +1.0%+54%+1.0%
- Royalty$27.5M$27.5Mquarter on quarter +53%year on year -9.4%+53%-9.4%
- Manufacturing$20.9M$20.9Mquarter on quarter +414%year on year +183%+414%+183%
Drug Manufacturers, Specialty & Generic
Ranks #17 of 41 by RyuScore